Roth Capital Partners Initiates Coverage on Mydecine, With Buy Rating And C$3 Price Target

Roth Capital Partners is initiating coverage of Mydecine with a Buy rating and $3/share price target. Mydecine is the first to treat PTSD and smoking cessation with the natural form of psilocybin (MYCO – 001).

‍

Full Report (Link)

‍